As both POLQi and STING agonists are currently under development, our findings demonstrate a synergy between these 2 targets representing what we believe is a promising strategy to combine DNA damage repair and immunotherapy against HR-deficient pancreatic cancer. Here, STING1 is linked to pancreatic neoplasm.